Sandoz shares slipped following a conservative sales forecast, prompting fresh questions about pricing power and volume growth in the generic drug sector.

Novartis boosted its full-year earnings guidance on resilient core portfolio momentum, even as late-stage clinical trial hurdles pressured bottom-line results.